Alexion Pharmaceuticals, Inc. is a pharmaceutical company that aims to enhance and provide revitalized therapies for patients with life-threatening and rare diseases. It has been its goal to discover and develop medical breakthroughs in biologic therapeutic products that are aimed at treating patients with rare, life-threatening diseases, including cancer and autoimmune disorders, hematologic, kidney and neurologic diseases, and transplant rejections.

Alexion Pharmaceuticals was established in 1992 in New Haven, Connecticut. But it was in 1996 that it became a public company (NASDAQ:ALLXN). In 1998, it began the first in-human clinical trial for eculizumab. And in 2007, Alexion’s eculizumab was sold under the trade name Soliris which was approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of patients with paroxysmal nocturnal haemoglobinuri (PNH). Throughout the years, many other breakthroughs and milestones in the field of treating life-threatening diseases were accomplished by Alexion. Also, it was able to acquire Synageva BioPharma, which strengthened its pipeline in establishing a metamorphic franchise with the addition of Kanuma, which was approved as a treatment for patients with hypophosphatasia (HPP)

It was added to the NASDAQ-100 Index in 2011, and only a year after, to the Standard & Poor’s 500 Index. As of 2017, Alexion Pharmaceuticals shares are mostly held by institutional investors (Fidelity Investments, T. Rowe Price, BlackRock and others).

Alexion Pharmaceuticals Headquarters Address

Traded as NASDAQ: ALXN
Industry focused Pharmaceutical
Founded in 1992
Founder Leonard Bell
Headquarters/Based in New Haven, Connecticut, U.S.
Products Branded and generic pharmaceutical products

Alexion Contacts

  • Location: Alexion Pharmaceuticals Inc. 100 College St. NEW HAVEN 06510-3210 United States USA
  • Phone number number: +1 (203) 272-2596
  • Fax: +1 (203) 271-8198
  • Website:

Products and Services

Alexion delivers life-changing therapies for patients with life-threatening and rare metabolic disorders: Kanuma (sebelipase alfa) and Strensiq (asfotase alfa). Kanuma is for the treatment of patients with lysosomal acid lipase deficiency (LAL-D), while Strensiq is especially made for patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)

Alexion developed Eculizumab, sold under the trade name Soliris, which is used in the treatment of two chronic, rare diseases caused by an uncontrolled activation of a branch of the immune system called the complement system. These diseases are paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is likewise approved in the European Union for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Key People/Executives for Alexion Pharmaceuticals

David Richard Brennan Chairman
Dr. Ludwig N. Hantson Ph.D. Chief Executive Officer & Director
Ms. Julie O’Neill M.B.A. Executive VP of Global Operations
Dr. David John Anderson M.B.A. Sr. Adviser to the Chief Executive Officer
Mr. Paul L. Clancy M.B.A CFO and Chief Executive VP
Daniel A Bazarko CPA Chief Accounting Officer and Sr. VP

Alexion Pharmaceuticals, Inc. Subsidiaries

Alexion Delaware Holding LLC Alexion Europe SAS
Alexion Cambridge Corporation Alexion Pharma France
Alexion Bermuda L.P.   Alexion Pharma Germany GmbH
 Alexion Holding B.V. Alexion Pharma Israel Ltd.
Alexion Pharma International Sarl Alexion Pharma Italy Sarl
 Alexion Pharma Argentina SRL Alexion Pharma GK
Alexion Pharmaceuticals Australasia PTY LTD Alexion Pharma Mexico, S. de R.L. de C.V.
 Alexion Pharma Belgium Sarl  Alexion Pharma Spain S.L.
 Ltda. (doing business as Alexion Latina America)  Alexion Medical Services Sarl
Alexion Pharma Canada Corp. Alexion İlaç Ticaret Limited Şirketi
Alexion Pharma Colombia SAS  Alexion Pharma UK


When Soliris, an Alexion-pioneered pharmaceutical product, was first approved in March 2007, the company’s peak annual sales were estimated at $150 million. And by September 2013, quarterly sales of Soliris went up to $400 million. Sales during the first quarter of 2015 were over US$600 million. And as of the first quarter of 2017, Alexion’s total revenues is already worth $870 Million, a 24% increase and 26% volume increase year-over-year
Before Alexion’s announcement of the Synageva BioPharma purchase amounting to $8.4 billion, the company was valued at $34 billion. In the last five years, it saw an increase in stock up to 800% and is currently trading at 46 times estimated earnings. The niche nature of its market as well as the high cost of Soliris, its key revenue driver, enabled the company a high-profit margin.